clinical trial · NCT06530030
Goal Attainment and Physical Activity in People With Hemophilia A
Hemophilia Aefanesoctocog alfa
brief summary
This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan. This study aims to enroll 35 patients.
started
Nov 26, 2024
primary completion
Sep 18, 2025
completion
Sep 18, 2025
last updated
Jan 20, 2026
official title
Prospective, Observational Study of the Impact of Efanesoctocog Alfa (ALTUVIIIO®) on Goal Attainment and Physical Activity in People With Moderate or Severe Hemophilia A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol